Raludotatug Deruxtecan (NCT06780085)

Name: Raludotatug Deruxtecan trial for Carcinoma, Non-Small-Cell Lung (NCT06780085)
Uploaded: 2026-10-31T05:22:45.192Z
Duration: 1 min 16 s
Description: Raludotatug Deruxtecan trial for Carcinoma, Non-Small-Cell Lung (NCT06780085). Who can join, how the treatment is intended to work, treatment groups and recruiting sites for NCT06780085.

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01): a one-minute explainerNCT067800851 min

Raludotatug Deruxtecan trial for Carcinoma, Non-Small-Cell Lung (NCT06780085). This is a short film with English narration. The transcript is on this page, and the written brief is separate.

What the film says

Read the transcript

This trial is for adults with stage IV nonsquamous lung cancer progressing after both checkpoint immunotherapy and platinum chemotherapy. Primary targeted therapy must not be indicated. Prior docetaxel or lung radiation excludes participation; a new biopsy is required.

The idea: compare intravenous raludotatug deruxtecan, ifinatamab deruxtecan or docetaxel every three weeks. The investigational antibodies carry cell-killing payloads to CDH6- or B7-H3-bearing cells, respectively. Researchers measure tumor response and side effects.

This phase 2 study plans 96 patients. Merck sponsors it; four US locations list recruitment.

Public record; not medical advice.

Read the full brief →

Already in a trial?

It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.

Organize my trial

7-day free trial, then $9 a month. Cancel anytime.